Optimal Use of Combined Modality Therapy in the Treatment of Esophageal Cancer

Talha Shaikh; Joshua E Meyer; Eric M Horwitz

doi:10.1016/j.soc.2017.01.009

Optimal Use of Combined Modality Therapy in the Treatment of Esophageal Cancer

Surg Oncol Clin N Am. 2017 Jul;26(3):405-429. doi: 10.1016/j.soc.2017.01.009. Epub 2017 May 11.

Authors

Talha Shaikh¹, Joshua E Meyer¹, Eric M Horwitz²

Affiliations

¹ Department of Radiation Oncology, Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA 19111, USA.
² Department of Radiation Oncology, Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA 19111, USA. Electronic address: eric.horwitz@fccc.edu.

PMID: 28576180
DOI: 10.1016/j.soc.2017.01.009

Abstract

Esophageal cancer is associated with a poor prognosis with 5-year survival rates of approximately 15% to 20%. Although patients with early stage disease may adequately be treated with a single modality, combined therapy typically consisting of neoadjuvant chemoradiation followed by esophagectomy is being adopted increasingly in patients with locally advanced disease. In patients who are not surgical candidates, definitive chemoradiation is the preferred treatment approach. All patients with newly diagnosed esophageal cancer should be evaluated in the multidisciplinary setting by a surgeon, radiation oncologist, and medical oncologist owing to the importance of each specialty in the management of these patients.

Keywords: Chemoradiation; Esophageal cancer; Esophagectomy; IMRT; Trimodality.

Publication types

Review

MeSH terms

Adenocarcinoma / surgery*
Adenocarcinoma / therapy
Chemoradiotherapy
Combined Modality Therapy / methods*
Esophageal Neoplasms / mortality
Esophageal Neoplasms / pathology
Esophageal Neoplasms / therapy*
Esophagectomy / methods*
Humans
Neoadjuvant Therapy / methods*
Neoplasm Staging
Survival Analysis
Survival Rate
Treatment Outcome